螺[咪唑烷-4,3'-吲哚啉]-2,2',5-三酮 | 57242-71-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: 螺[咪唑烷-4,3'-吲哚啉]-2,2',5-三酮
• 英文名称: spiro[imidazolidine-4,3'-indoline]-2,2',5-trione
• 英文别名: 1'H-spiro[imidazolidine-4,3'-indole]-2,5,2'-trione；spiro[imidazoline-4,3'-indoline]-2,2',5-trione；spiro[1H-indole-3,5'-imidazolidine]-2,2',4'-trione
• CAS: 57242-71-4
• 化学式: C₁₀H₇N₃O₃
• mdl: MFCD24390321
• 分子量: 217.184
• InChiKey: VCZILNWKBJBQGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  87.3
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  螺[咪唑烷-4,3'-吲哚啉]-2,2',5-三酮 在 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 8.0h， 生成 2-(2,2',5-trioxospiro[imidazolidine-4,3'-indoline]-1-yl)acetic acid
  参考文献：
  名称：

  [EN] SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE
  [FR] INHIBITEURS DE HAT SPIROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  具有式（IX）的结构或其立体异构体、互变异构体或药学上可接受的盐的化合物，其中R1、R2a、R2b、R3a、R3b、R4a、R4b、Q1----Q2、R6、R7、A、B、W、x和y如本文所定义，并提供。还提供了包括这些化合物的药物组合物和通过给予这些化合物治疗各种HAT相关疾病或疾病，包括癌症的方法。

  公开号：

  WO2016044770A1
• 作为产物：
  描述：

  靛红 以62%的产率得到
  参考文献：
  名称：

  OTOMASU H.; NATORI K.; TAKAHASHI H., CHEM. AND PHARM. BULL. , 1975, 23, NO 7, 1431-1435

  摘要：

  DOI：

文献信息

• Spiro [imidazolidine 4,3'-indoline]2,2',5-triones, compositions and use
  申请人：Imperial Chemical Industries PLC

  公开号：US04386100A1

  公开（公告）日：1983-05-31

  The invention provides novel non-toxic biodegradable derivatives of the formula: ##STR1## wherein Ra is (1-12C)alkyl, phenyl, naphthylmethyl or cinnamyl, the aromatic rings of which optionally bear one or two halogeno substituents, or Ra is benzyl optionally bearing up to 3 substituents independently selected from halogeno, trifluoromethyl, (1-4C)alkyl, (1-4C)alkoxy, nitro, cyano and hydroxy; Rb and Rc are independently selected from hydrogen and non-toxic biodegradable protecting radicals, but are not both hydrogen; and benzene ring A optionally bears one substituent selected from halogeno, (1-4C)alkyl, (1-4C)alkoxy, nitro and hydroxy, or bears two substituents independently selected from halogeno, (1-4C)alkyl and nitro; pharmaceutical compositions thereof; and processes for their manufacture. The amides of formula I in which Rb.dbd.Rc.dbd.H are potent inhibitors of the enzyme aldose reductase. The derivatives of formula I provided by the invention are of use in vivo in the treatment or prophylaxis of certain complications of diabetes or galactosemia.

  该发明提供了新型的非毒性可生物降解衍生物，其化学式为：##STR1## 其中Ra是(1-12C)烷基、苯基、萘基甲基或肉桂基，其芳环上可选地带有一个或两个卤素取代基，或Ra是苄基，可选地带有高达3个取代基，这些取代基独立选择自卤素、三氟甲基、(1-4C)烷基、(1-4C)烷氧基、硝基、氰基和羟基；Rb和Rc独立选择自氢和非毒性可生物降解保护基团，但不能都是氢；苯环A可选地带有一个取代基，选择自卤素、(1-4C)烷基、(1-4C)烷氧基、硝基和羟基，或带有两个取代基，这些取代基独立选择自卤素、(1-4C)烷基和硝基；以及其制备方法和药物组合物。其中Rb=dbd.Rc=dbd.H的化合物是醛糖还原酶酶的有效抑制剂。该发明提供的式I衍生物在体内用于治疗或预防某些糖尿病或半乳糖血症的并发症。
• 1'-Substituted spiro[imidazolidine-4,3'-indoline]2,2',5-triones
  申请人：Imperial Chemical Industries PLC

  公开号：US04490381A1

  公开（公告）日：1984-12-25

  The invention concerns novel 1'-substituted spiro[imidazolidine-4,3'-indoline]-2,2',5-triones of the formula: ##STR1## in which R.sup.1 is (1-12C)alkyl; phenyl, naphthylmethyl or cinnamyl optionally bearing 1-2 halogeno substituents; or benzyl optionally bearing 1-3 substituents independently selected from halogeno, trifluoromethyl, (1-4C)-alkyl, (1-4C)alkoxy, nitro, cyano and hydroxy; and ring A optionally bears one substituent selected from halogeno, (1-4C)alkyl, (1-4C)alkoxy, nitro and hydroxy, or two substituents independently selected from halogeno (1-4C)alkyl and nitro; or a pharmaceutically acceptable salt thereof; but excluding those compounds wherein R.sup.1 is methyl, ethyl, n-propyl or unsubstituted benzyl and benzene ring A is unsubstituted. The compounds of the invention are potent inhibitors of the enzyme aldose reductase and are of use in the treatment or prophylaxis of certain complications of diabetes or galactosemia. The invention also embraces processes for the manufacture of the novel compounds of formula I, as well as pharmaceutical compositions of such compounds. A representative compound is 1'-(2-fluoro-4-bromobenzyl)-spiro]imidazolidine-4,3'-indoline]-2,2',5-trio ne.

  本发明涉及新型的1'-取代的螺[咪唑啉-4,3'-吲哚]-2,2',5-三酮，其化学式为：##STR1## 其中R.sup.1为(1-12C)烷基；苯基，萘基甲基或肉桂基，可选地带有1-2个卤素取代基；或苄基，可选地带有1-3个独立选择的取代基，包括卤素，三氟甲基，(1-4C)-烷基，(1-4C)烷氧基，硝基，氰基和羟基；环A可选地带有一个卤素，(1-4C)烷基，(1-4C)烷氧基，硝基和羟基取代基，或两个独立选择的卤素(1-4C)烷基和硝基取代基；或其药学上可接受的盐；但不包括R.sup.1为甲基，乙基，正丙基或未取代苄基，且苯环A未取代的化合物。本发明的化合物是醛糖还原酶酶的有效抑制剂，可用于治疗或预防糖尿病或半乳糖血症的某些并发症。本发明还涵盖了制造式I的新型化合物的方法，以及这些化合物的制药组合物。代表性化合物是1'-(2-氟-4-溴苄基)-螺[咪唑啉-4,3'-吲哚]-2,2',5-三酮。
• Tricyclic spiro derivatives as CRTH2 modulators
  申请人：Schwarz Matthias

  公开号：US20090318486A1

  公开（公告）日：2009-12-24

  The present invention is related to the use of spiro derivatives of Formula (I) for the treatment and/or prevention of allergic diseases, inflammatory dermatoses and other diseases with an inflammatory component. Specifically, the present invention is related to the use of spiro derivatives for the modulation of CRTH2 activity.

  本发明涉及使用式(I)的螺环衍生物用于治疗和/或预防过敏性疾病、炎症性皮肤病和其他具有炎症成分的疾病。具体而言，本发明涉及使用螺环衍生物来调节CRTH2活性。
• Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1
  申请人：Horoszok Lucy

  公开号：US20090076049A1

  公开（公告）日：2009-03-19

  The present invention relates to new compounds of formula (I), wherein R 1 to R 9 and X are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

  本发明涉及公式（I）的新化合物，其中R1到R9和X如公式I中所定义，或其盐，溶剂合物或溶剂化盐，其制备过程以及用于制备的新中间体，含有所述化合物的制药配方以及所述化合物在治疗中的应用。
• SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE
  申请人：ABBVIE INC.

  公开号：US20160235716A1

  公开（公告）日：2016-08-18

  Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R 1 , R 2a , R 2b , R 3a , R 3b , R 4a , R 4b , Q 1 - - - -Q 2 , R 6 , R 7 , A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

  提供具有如下式（IX）的结构，或其立体异构体、互变异构体或药学上可接受的盐，其中R1、R2a、R2b、R3a、R3b、R4a、R4b、Q1- - - -Q2、R6、R7、A、B、W、x和y在此处定义并给出。还提供包括这些化合物的制药组合物和通过给予这些化合物的治疗各种HAT相关疾病或疾病，包括癌症的方法。